John Hainsworth

Summary

Affiliation: Sarah Cannon Cancer Center
Country: USA

Publications

  1. ncbi request reprint Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Clin Oncol 20:2937-42. 2002
  2. ncbi request reprint Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care
    John D Hainsworth
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN, USA
    Virchows Arch 464:393-402. 2014
  3. doi request reprint Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Invest 31:323-9. 2013
  4. doi request reprint Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 31:217-23. 2013
  5. ncbi request reprint Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 10:240-6. 2012
  6. ncbi request reprint Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute Tennessee Oncology, PLLC, Nashville, Tennessee, USA
    Cancer 110:2027-34. 2007
  7. ncbi request reprint Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Genitourin Cancer 5:278-83. 2007
  8. ncbi request reprint Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 25:1747-52. 2007
  9. ncbi request reprint Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Cancer Invest 24:469-73. 2006
  10. ncbi request reprint Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 24:3548-54. 2006

Detail Information

Publications100

  1. ncbi request reprint Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Clin Oncol 20:2937-42. 2002
    ..To provide long-term follow-up on the survival of patients with advanced non-small-cell lung cancer treated with paclitaxel/carboplatin-based regimens in a multicenter, community-based setting...
  2. ncbi request reprint Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care
    John D Hainsworth
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN, USA
    Virchows Arch 464:393-402. 2014
    ..Site-specific treatment, based on tissue of origin diagnosis, should replace empiric chemotherapy in patients with CUP...
  3. doi request reprint Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Invest 31:323-9. 2013
    ..To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC)...
  4. doi request reprint Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 31:217-23. 2013
    ..However, the clinical value of these molecular predictions is unknown. We used tumor profiling results to direct site-specific therapy for patients with CUP...
  5. ncbi request reprint Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 10:240-6. 2012
    ....
  6. ncbi request reprint Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute Tennessee Oncology, PLLC, Nashville, Tennessee, USA
    Cancer 110:2027-34. 2007
    ..The aim of this study was to compare the efficacy of single-agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC)...
  7. ncbi request reprint Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Genitourin Cancer 5:278-83. 2007
    ..For this reason, we evaluated the efficacy of docetaxel plus bortezomib in the first-line treatment of patients with HRPC...
  8. ncbi request reprint Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 25:1747-52. 2007
    ..We therefore have evaluated the efficacy and toxicity of this combination in patients with CUP...
  9. ncbi request reprint Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Cancer Invest 24:469-73. 2006
    ..Epirubicin, a doxorubicin analog, has shown modest toxicity advantages when compared to the parent compound. In this Phase II trial, we evaluated the activity and toxicity of a docetaxel/epirubicin combination...
  10. ncbi request reprint Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 24:3548-54. 2006
    ..To evaluate the efficacy of chemotherapy with paclitaxel, carboplatin, and etoposide in advanced adult poorly differentiated neuroendocrine carcinomas...
  11. ncbi request reprint Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN E mail
    Clin Genitourin Cancer 4:287-92. 2006
    ..This phase II study was performed as a preliminary evaluation of the feasibility and efficacy of weekly docetaxel/estramustine in patients with prostate cancer and increasing serum PSA levels. Patients and..
  12. ncbi request reprint Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 23:7889-96. 2005
    ....
  13. ncbi request reprint Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    Cancer 104:1992-7. 2005
    ..The current study was performed to evaluate the activity of combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site...
  14. doi request reprint Treatment for patients with unknown primary cancer and favorable prognostic factors
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN, USA
    Semin Oncol 36:44-51. 2009
    ..This review summarizes current recommendations for the evaluation and treatment of patients in each of these favorable prognostic subsets...
  15. ncbi request reprint Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    Cancer 103:2298-303. 2005
    ..The objective of the current study was to evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel, carboplatin, and gemcitabine in patients with advanced urothelial carcinoma...
  16. ncbi request reprint Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Gynecol Oncol 97:200-5. 2005
    ..To evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and etoposide in the first-line treatment of patients with stage III or IV adenocarcinoma of the ovary...
  17. ncbi request reprint Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:1088-95. 2005
    ..To compare the benefit of maintenance rituximab therapy versus rituximab re-treatment at progression in patients with previously treated indolent non-Hodgkin's lymphoma...
  18. doi request reprint Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 112:1288-95. 2008
    ....
  19. doi request reprint Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Genitourin Cancer 5:427-32. 2007
    ....
  20. doi request reprint Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 113:765-71. 2008
    ..The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma...
  21. doi request reprint Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN, USA
    Cancer J 17:267-72. 2011
    ..The aim of the study was to evaluate the feasibility and efficacy of adding bevacizumab and erlotinib to concurrent chemoradiation therapy for first-line treatment of patients with locally advanced squamous carcinoma of the head and neck...
  22. doi request reprint A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Invest 29:451-5. 2011
    ..To evaluate the activity of panobinostat in refractory renal carcinoma...
  23. doi request reprint A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Thorac Oncol 5:1630-6. 2010
    ..AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  24. doi request reprint Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer 116:4122-9. 2010
    ....
  25. doi request reprint Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 116:3663-9. 2010
    ....
  26. doi request reprint Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma
    John D Hainsworth
    Sarah Cannon Research Institute, 3322 West End Ave, Suite 900, Nashville, TN 37203, USA
    J Clin Oncol 28:2131-6. 2010
    ..To evaluate the efficacy and toxicity of the combination of bevacizumab, an angiogenesis inhibitor, and everolimus, an mTOR inhibitor, in the treatment of patients with advanced clear cell renal carcinoma...
  27. doi request reprint Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lymphoma Myeloma Leuk 10:44-50. 2010
    ..In this phase II trial, we treated this group of patients with a novel regimen containing 3 courses of rituximab/chemotherapy followed by maintenance rituximab...
  28. doi request reprint Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 116:2448-54. 2010
    ..In the current study, the combination of oxaliplatin and capecitabine in patients with recurrent and refractory CUP was examined...
  29. doi request reprint Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN, USA
    Cancer J 16:70-5. 2010
    ..To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide (PCE) versus gemcitabine/irinotecan, both followed by single-agent gefitinib, in patients with carcinoma of unknown primary site...
  30. doi request reprint Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site
    John D Hainsworth
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, Tennessee 37203, USA
    Oncologist 14:1189-97. 2009
    ..This phase II trial evaluated the efficacy and toxicity of the combination of paclitaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with carcinoma of unknown primary site (CUP)...
  31. doi request reprint Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Lymphoma Myeloma 9:223-8. 2009
    ..To evaluate the efficacy and safety of treatment with Yttrium-90 (90Y) ibritumomab tiuxetan following completion of short-course rituximab/chemotherapy in patients with previously untreated follicular non-Hodgkin lymphoma...
  32. doi request reprint Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Cancer 115:2138-46. 2009
    ..The authors evaluated the feasibility, toxicity, and efficacy of gefitinib added to first-line combined-modality therapy for patients with locally advanced squamous carcinoma of the head and neck...
  33. ncbi request reprint Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Clin Oncol 23:1500-6. 2005
    ..To evaluate the feasibility and efficacy of rituximab with short-duration chemotherapy in the first-line treatment of patients with follicular non-Hodgkin's lymphoma (NHL)...
  34. ncbi request reprint A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours
    John Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Anticancer Drugs 14:S13-9. 2003
    ..This paper reviews the results from three trials of ZD9331, a novel, direct-acting antifolate, in patients with relapsed or refractory solid tumours...
  35. ncbi request reprint Diagnosis, staging, and clinical characteristics of the patient with mediastinal germ cell carcinoma
    John D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA
    Chest Surg Clin N Am 12:665-72. 2002
    ..Further details regarding the treatment of mediastinal germ cell tumors are presented elsewhere in this issue...
  36. ncbi request reprint Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 110, Nashville, TN 37203, USA
    Cancer Invest 20:863-71. 2002
    ..In this phase II trial, we evaluated the combination of paclitaxel and mitoxantrone in an attempt to maintain efficacy and improve tolerability of this regimen...
  37. ncbi request reprint Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Nashville, TN 37203, USA
    J Clin Oncol 21:1746-51. 2003
    ....
  38. ncbi request reprint Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Nashville, TN, USA
    J Clin Oncol 20:4261-7. 2002
    ....
  39. ncbi request reprint Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Cancer Invest 21:193-9. 2003
    ..However, novel treatment approaches are necessary before substantial improvements in treating this patient population will be realized...
  40. ncbi request reprint First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial
    John D Hainsworth
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, 37203, USA
    Clin Lymphoma 4:36-42. 2003
    ..This regimen provides a treatment option for elderly patients who are not considered candidates for standard CHOP/rituximab chemotherapy...
  41. ncbi request reprint Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    The Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer 94:2426-33. 2002
    ....
  42. ncbi request reprint Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial
    John D Hainsworth
    The Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Clin Lung Cancer 5:33-8. 2003
    ..A randomized comparison of this regimen versus single-agent weekly docetaxel is in progress...
  43. ncbi request reprint Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network
    J D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Nashville, TN 37203, USA
    Cancer 92:2391-8. 2001
    ..The current study was conducted to evaluate the feasibility, toxicity, and efficacy of weekly docetaxel when paired with either gemcitabine or vinorelbine as the second-line treatment of patients with advanced nonsmall cell lung carcinoma...
  44. ncbi request reprint Practical aspects of weekly docetaxel administration schedules
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Oncologist 9:538-45. 2004
    ..The results of these ongoing studies will further define the place of weekly docetaxel in cancer therapy...
  45. ncbi request reprint A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer
    John D Hainsworth
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:33-42. 2004
    ..Postoperative complications associated with this preoperative combined-modality regimen were more frequent than expected with resection alone...
  46. pmc Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, Tennessee, USA
    Arthritis Res Ther 5:S12-6. 2003
    ..Current data suggest that the safety profile of rituximab in patients with RA is similar to that in oncology, but that the adverse events are less frequent and less severe in patients with RA...
  47. ncbi request reprint Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network
    J D Hainsworth
    Sarah Cannon Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA
    Cancer Invest 19:335-9. 2001
    ..Because gemcitabine has activity against a variety of adenocarcinomas, further evaluation of this agent as part of first-line therapy for patients with carcinoma of unknown primary site is appropriate...
  48. ncbi request reprint Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial
    J D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Clin Oncol 19:3500-5. 2001
    ..To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly or poor-performance status patients with advanced breast cancer...
  49. ncbi request reprint Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial
    John D Hainsworth
    The Sarah Cannon Cancer Center Tennessee Oncology, Nashville, Tennessee, USA
    Cancer 100:2437-41. 2004
    ....
  50. doi request reprint A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer
    Denise Yardley
    Sarah Cannon Research Institute, 3322 West End Avenue Suite 900, Nashville, TN 37203, USA
    Breast Cancer Res Treat 123:471-5. 2010
    ..Further investigation of the role of nab-paclitaxel in adjuvant breast cancer therapy is indicated, but definitive evaluation will require randomized phase III trials...
  51. doi request reprint A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies
    David Spigel
    The Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer Invest 29:308-12. 2011
    ..Twice-daily vatalanib dosing improved tolerability and ease of full-dose administration. These results suggest that vatalanib-containing combinations may be active and tolerable, warranting further study...
  52. ncbi request reprint Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
    Howard Burris
    The Sarah Cannon Cancer Center Tennessee Oncology, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 22:1621-9. 2004
    ..To assess the feasibility and toxicity of weekly paclitaxel/carboplatin with or without trastuzumab following initial treatment with trastuzumab...
  53. ncbi request reprint Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial
    Anthony A Meluch
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer J 9:251-60. 2003
    ..This phase II study was designed to determine the feasibility, toxicity, and therapeutic efficacy of a novel outpatient combined-modality preoperative regimen in patients with localized esophageal cancer...
  54. ncbi request reprint Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    J Thorac Oncol 2:854-61. 2007
    ..Imatinib targets KIT expression, providing rationale for studying its role in combination with chemotherapy in SCLC in a multicenter phase II trial...
  55. ncbi request reprint Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies
    Suzanne Jones
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville 37203, USA
    Invest New Drugs 20:55-61. 2002
    ..Higher doses of JM-216 are associated with more severe thrombocytopenia and delayed hematologic recovery resulting in subsequent dosing delays...
  56. ncbi request reprint Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer
    William West
    Response Oncology, Memphis, Tennessee, USA
    Oncologist 8:76-82. 2003
    ..Additional studies of topotecan and paclitaxel at these dose levels are needed to fully elucidate the efficacy of this combination in extensive SCLC...
  57. ncbi request reprint Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Cancer J 8:311-21. 2002
    ..The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of a novel combined-modality treatment for patients with locally advanced squamous carcinoma of the head and neck...
  58. doi request reprint A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer Invest 28:865-71. 2010
    ..8 months). Substitution of oxaliplatin for cisplatin or carboplatin, in combination with trastuzumab, does not appear to improve first-/second-line therapy in HER2-positive MBC...
  59. doi request reprint A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennesee, USA
    Cancer Invest 28:925-31. 2010
    ..The vinflunine/trastuzumab combination was active and well tolerated, but our results do not suggest advantages over taxane/trastuzumab or vinorelbine/trastuzumab...
  60. ncbi request reprint A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies
    Suzanne F Jones
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville 37203, USA
    Oncologist 7:444-50. 2002
    ..This phase I study was conducted to determine the dose-limiting toxicity (DLT), maximum-tolerated doses, and recommended phase II doses of the combination of weekly intravenous paclitaxel and oral eniluracil/5-fluorouracil (5-FU)...
  61. doi request reprint Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:237-42. 2009
    ..The efficacy of weekly docetaxel is not improved by concurrent administration of imatinib as a PDGFR inhibitor...
  62. doi request reprint Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium
    John D Hainsworth
    Sarah Cannon Research Institute Nashville, Tennessee 37203, USA
    Cancer Invest 28:275-9. 2010
    ..Treatment was well tolerated, with myelosuppression as the only frequent toxicity. Vinflunine has a low level of activity in the treatment of refractory metastatic prostate cancer, and should not be further developed for this indication...
  63. doi request reprint A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN, USA
    Clin Breast Cancer 10:217-23. 2010
    ..We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docetaxel was administered weekly to decrease myelosuppression...
  64. ncbi request reprint A Phase I trial of protracted oral fixed-dose temozolomide
    Suzanne F Jones
    The Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 104:1985-91. 2005
    ..The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis...
  65. doi request reprint A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Breast Cancer 8:425-31. 2008
    ....
  66. doi request reprint A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Breast Cancer 8:242-8. 2008
    ..Because docetaxel might be more active than paclitaxel in the treatment of metastatic breast cancer, we explored the feasibility of substituting docetaxel for paclitaxel in dose-dense adjuvant therapy...
  67. ncbi request reprint Phase I. Trial of irinotecan plus carboplatin in two dose schedules
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:36-40. 2003
    ..With this amended regimen, the recommended phase II doses are irinotecan at 90 mg/m2 in combination with carboplatin at AUC 2.0 on days 1 and 8, with treatment cycles repeated every 21 days...
  68. doi request reprint Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 112:2749-55. 2008
    ..S. Food and Drug Administration approval...
  69. ncbi request reprint A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:862-6. 2010
    ..In this multicenter, community-based phase II trial, we evaluated carboplatin and weekly topotecan in the previously untreated patients with extensive stage SCLC...
  70. doi request reprint Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer
    Howard A Burris
    Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN 37203, USA
    Cancer Invest 28:408-12. 2010
    ..These results do not support further investigation of thalidomide for MBC. The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors...
  71. ncbi request reprint Phase I. Trial of irinotecan and temozolomide in patients with solid tumors
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:41-5. 2003
    ..The recommended phase II doses of irinotecan and temozolomide on treatment arms 1 and 3 remain to be determined as patient accrual is currently ongoing...
  72. ncbi request reprint Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial
    F Anthony Greco
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA
    Oncologist 9:644-52. 2004
    ....
  73. ncbi request reprint Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial
    Anthony A Meluch
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer 98:2192-8. 2003
    ..The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone-refractory prostate carcinoma...
  74. ncbi request reprint Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 8:480-5, 498. 2010
    ..To examine FOLFOX/bevacizumab/cetuximab in the first-line treatment of metastatic colorectal cancer (mCRC)...
  75. ncbi request reprint Prolonging remission with rituximab maintenance therapy
    John D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Semin Oncol 31:17-21. 2004
    ..These include optimum schedule/duration, use after initial chemotherapy/rituximab combinations, efficacy versus retreatment at progression, and efficacy in other B-cell neoplasms...
  76. ncbi request reprint A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer
    Suzanne F Jones
    The Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:361-6. 2005
    ....
  77. doi request reprint Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction
    David R Spigel
    Sarah Cannon Research Institute, 3322 West End Ave, Suite 201, Nashville, TN 37203, USA
    J Clin Oncol 28:2213-9. 2010
    ..This multicenter community-based phase I/II trial examined a modern triplet regimen comprised of oxaliplatin, docetaxel, and capecitabine (ODC) combined with radiation therapy (RT)...
  78. ncbi request reprint Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Lung Cancer 8:483-7. 2007
    ....
  79. ncbi request reprint Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial
    F Anthony Greco
    The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville 37203, USA
    Cancer 95:1279-85. 2002
    ..The authors compared the toxicity, response rate, and progression free survival of four chemotherapy regimens for patients with advanced (Stage IIIB and IV) nonsmall cell lung carcinoma...
  80. doi request reprint Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:178-83. 2009
    ..We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC)...
  81. doi request reprint Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer
    Jeffrey R Infante
    Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Breast Cancer 9:23-8. 2009
    ..We investigated the feasibility and safety of a 3-drug combination of trastuzumab, docetaxel, and vinorelbine as first-line therapy in this patient group...
  82. doi request reprint Neuroendocrine carcinoma of unknown primary site
    David R Spigel
    Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, USA
    Semin Oncol 36:52-9. 2009
    ..Tumor grade/differentiation currently is an important determinant of the management of these patients, and therapy in the future will be based on a more precise knowledge of the unique biology of these tumors...
  83. ncbi request reprint Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial
    F Anthony Greco
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Oncologist 10:728-33. 2005
    ..gsk.com) with paclitaxel, carboplatin (Paraplatin; Bristol-Myers Squibb), and etoposide (Etopophos, VePesid; Bristol-Myers Squibb) in patients with previously untreated extensive-stage small cell lung cancer...
  84. doi request reprint Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 4:1555-60. 2009
    ..Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted in patients with untreated extensive-stage SCLC...
  85. ncbi request reprint Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Lung Cancer 7:127-32. 2005
    ..Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients...
  86. doi request reprint Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
    David R Spigel
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 28:43-8. 2010
    ..Strategies to safely incorporate novel antiangiogenic agents into combined-modality therapy in lung cancer are needed...
  87. ncbi request reprint Phase II trial of vinflunine in relapsed small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:874-8. 2010
    ..Vinflunine is a new microtubule inhibitor with preclinical activity in small cell lung cancer (SCLC). In this phase II trial, we evaluated vinflunine in patients with relapse-sensitive and refractory SCLC...
  88. doi request reprint Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lung Cancer 11:198-203. 2010
    ..This multicenter, community-based trial was designed to examine the role of cetuximab in combination with a nonplatinum regimen...
  89. pmc Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction
    F Anthony Greco
    Tennessee Oncology, PLLC, Nashville, Tennessee, USA
    Oncologist 15:500-6. 2010
    ..This retrospective, multi-institutional study evaluated the accuracy of tissue-of-origin prediction by molecular profiling in patients with carcinoma of unknown primary site (CUP)...
  90. doi request reprint Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:841-5. 2010
    ..Pemetrexed and gemcitabine are safe and active non-small cell lung cancer (NSCLC) therapies when administered every 3 weeks. Biweekly scheduling was studied in this phase II trial...
  91. ncbi request reprint Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study
    F Anthony Greco
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Centennial Medical Center, Nashville, TN 37203, USA
    J Clin Oncol 20:1651-6. 2002
    ..To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site...
  92. doi request reprint ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
    Bruce E Johnson
    Bruce E Johnson, Dana Farber Cancer Institute, Boston, MA Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo Chin Yu Lin and Chris Bowden, Genentech, South San Francisco Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA John Hainsworth, Sarah Cannon Research Institute, Nashville, TN Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA Bruce Kressel, Sibley Memorial Hospital, Washington, DC Thomas Marsland, Integrated Community Oncology Network, Orange Park Mark Rubin, Florida Cancer Specialists, Fort Myers, FL Taral Patel, The Mark H Zangmeister Center, Columbus, OH Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York,
    J Clin Oncol 31:3926-34. 2013
    ..This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-small-cell lung cancer (NSCLC)...
  93. ncbi request reprint Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer
    Herbert I Hurwitz
    Department of Medical Oncology and Transplantation, Room 25132, Morris Building, Box 3052, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 23:3502-8. 2005
    ..Here, we describe efficacy and safety results for the third patient cohort in this trial, who received BV combined with FU/LV, and compare them with results for concurrently enrolled patients who received IFL...
  94. ncbi request reprint Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial
    John D Hainsworth
    Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, TN
    Semin Oncol 29:25-9. 2002
    ..The initial response rate can be improved by using scheduled maintenance courses of rituximab administered every 6 months. Final information regarding duration of response and time to progression awaits further follow-up...
  95. ncbi request reprint Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
    Gary J Schiller
    UCLA Division of Hematology Oncology, University of California Los Angeles, San Diego, CA 90095, USA
    J Clin Oncol 24:2456-64. 2006
    ..To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS)...
  96. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...
  97. ncbi request reprint Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
    Frank A Scappaticci
    Genentech, Inc, South San Francisco, CA 94080, USA
    J Surg Oncol 91:173-80. 2005
    ..Because antiangiogenic agents might inhibit wound healing, we assessed postoperative wound healing complications in two randomized trials of 5 mg/kg bevacizumab in CRC treatment...
  98. doi request reprint Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4442-8. 2008
    ..To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site...
  99. doi request reprint Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
    Howard S Hochster
    New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA
    J Clin Oncol 26:3523-9. 2008
    ..To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC)...
  100. ncbi request reprint First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Semin Oncol 30:9-15. 2003
    ..Further follow-up will provide important information regarding the impact of first-line and maintenance rituximab on progression-free survival in patients with indolent non-Hodgkin's lymphoma...